BD
MCID: BHC003
MIFTS: 67

Behcet Syndrome (BD)

Categories: Rare diseases, Neuronal diseases, Eye diseases, Cardiovascular diseases, Nephrological diseases, Bone diseases, Skin diseases

Aliases & Classifications for Behcet Syndrome

MalaCards integrated aliases for Behcet Syndrome:

Name: Behcet Syndrome 57 12 76 53 25 44 38 73 53
Behcet's Syndrome 12 53 25 6 43
Behcet's Disease 38 12 53 54 15
Behcet Disease 57 25 37 55
Behçet Disease 53 25 59
Adamantiades-Behcet Disease 12 25
Triple Symptom Complex 12 25
Bd 57 53
Behcet Triple Symptom Complex 25
Old Silk Route Disease 25
Malignant Aphthosis 25
Behcet Disease; Bd 57
Behçet's Syndrome 53
Behet's Syndrome 12
Behçet's Disease 53
Behçet’s Disease 53

Characteristics:

Orphanet epidemiological data:

59
behçet disease
Inheritance: Multigenic/multifactorial; Prevalence: 1-5/10000 (Japan),>1/1000 (Turkey); Age of onset: Adolescent,Adult,Childhood; Age of death: adult;

OMIM:

57
Inheritance:
familial cases reported, but probably not mendelian


Classifications:



Summaries for Behcet Syndrome

NIH Rare Diseases : 53 Behçet disease is a chronic multisystem inflammatory disorder characterized by ulcers affecting the mouth and genitals, various skin lesions, and abnormalities affecting the eyes. In some people, the disease also results in arthritis (swollen, painful, stiff joints), skin problems, and inflammation of the digestive tract, brain, and spinal cord. Although it can happen at any age, symptoms generally begin when individuals are in their 20s or 30s. The disease is common in Japan, Turkey and Israel, and less common in the United States. The exact cause of Behçet disease is still unknown, but it is thought that it is an autoimmune disease, where the abnormal immune activity is triggered by exposure to an environmental agent (such as an infection) in people with a genetic predisposition to develop the disease. Research show that people with Behçet’s disease, especially those of Middle Eastern and Asian descent, have an increased frequency of certain “human leukocyte antigens” (HLAs), specifically HLA-B51, than the general population, which may increase the risk (predispose) to have the disease.  Treatment is symptomatic and supportive. Research is being conducted on the use of interferon-alpha and with agents which inhibit tumor necrosis factor (TNF) for the treatment of Behçet disease. Behçet disease is a lifelong disorder that comes and goes. Spontaneous remission over time is common for individuals with Behçet disease but permanent remission of symptoms has not been reported.

MalaCards based summary : Behcet Syndrome, also known as behcet's syndrome, is related to vasculitis and aphthous stomatitis, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Behcet Syndrome is MEFV (MEFV, Pyrin Innate Immunity Regulator), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Methylprednisolone and Prednisolone have been mentioned in the context of this disorder. Affiliated tissues include eye, skin and brain, and related phenotypes are seizures and ataxia

MedlinePlus : 43 Behcet's syndrome is a disease that involves vasculitis, which is inflammation of the blood vessels. It causes problems in many parts of the body. The most common symptoms are Sores in the mouth Sores on the sex organs Other skin sores Swelling of parts of the eye Pain, swelling and stiffness of the joints More serious problems can include meningitis, blood clots, inflammation of the digestive system and blindness. Doctors aren't sure what causes Behcet's. It is rare in the United States, but is common in the Middle East and Asia. It mainly affects people in their 20s and 30s. Diagnosing Behcet's can take a long time, because symptoms may come and go, and it may take months or even years to have all of the symptoms. There is no cure. Treatment focuses on reducing pain and preventing serious problems. Most people can control symptoms with treatment. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

NINDS : 54 Behcet's disease is a rare, chronic inflammatory disorder. The cause of Behcet's disease is unknown, but current research suggests that both genetic and  environmental factors play a role.  Behcet's disease generally begins when individuals are in their 20s or 30s, although it can happen at any age. It tends to occur more often in men than in women. Symptoms of Behcet's disease include recurrent ulcers in the mouth (resembling canker sores) and on the genitals, and eye inflammation. The disorder may also cause various types of skin lesions, arthritis, bowel inflammation, meningitis (inflammation of the membranes of the brain and spinal cord), and cranial nerve palsies. Behcet's is a multi-system disease; it may involve all organs and affect the central nervous system, causing memory loss and impaired speech, balance, and movement. The effects of the disease may include blindness, stroke, swelling of the spinal cord, and intestinal complications. The disease is common in the Middle East, particularly in Turkey, and in Far Eastern nations such as Japan and Korean, but is less common in the United States.

Disease Ontology : 12 A vasculitis that is characterized by an autoimmune mediated inflammation of the blood vessels throughout the body leading to ulcerations on the mouth and sometimes the genitals, notorious for causing hypopyon uveitis.

Wikipedia : 76 Behçet\'s disease (BD) is a type of inflammatory disorder which affects multiple parts of the body. The... more...

Description from OMIM: 109650

Related Diseases for Behcet Syndrome

Diseases related to Behcet Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 147)
# Related Disease Score Top Affiliating Genes
1 vasculitis 32.7 CRP MEFV TNF
2 aphthous stomatitis 31.5 HLA-B IL10 MEFV TNF
3 psoriatic juvenile idiopathic arthritis 11.5 MEFV NOD2 PSTPIP1
4 pouchitis 11.4 IL10 NOD2 TLR4
5 inflammatory myopathy with abundant macrophages 11.4 MEFV TNFRSF1A
6 intermittent hydrarthrosis 11.4 MEFV TNFRSF1A
7 microscopic polyangiitis 11.4 HLA-B IL10 TNF
8 periodic fever, familial, autosomal dominant 11.4 MEFV TNF TNFRSF1A
9 pyoderma gangrenosum 11.4 MEFV NOD2 PSTPIP1 TNF
10 pyoderma 11.4 MEFV NOD2 PSTPIP1 TNF
11 orofacial granulomatosis 11.4 IL10 NOD2 TNF
12 blau syndrome 11.4 MEFV NOD2 TNF
13 idiopathic achalasia 11.4 IL10 IL23R TNF
14 punctate inner choroidopathy 11.4 IL10 TNF
15 post-transplant lymphoproliferative disease 11.4 IL10 TNF TNFRSF1A
16 muckle-wells syndrome 11.4 CRP MEFV TNFRSF1A
17 intermediate uveitis 11.4 HLA-B IL10 TNF
18 polyarteritis nodosa 11.4 ADA2 CRP MEFV
19 wells syndrome 11.4 CRP MEFV TNFRSF1A
20 q fever 11.4 IL10 NOD2 TLR4 TNF
21 hematopoietic stem cell transplantation 11.4 HLA-B IL10 TNF
22 hypersensitivity vasculitis 11.4 C4A CRP MEFV
23 panuveitis 11.4 HLA-B IL10 TNF
24 hypersensitivity reaction type iii disease 11.4 C4A CRP MEFV
25 relapsing fever 11.4 CRP MEFV TNF TNFRSF1A
26 acute graft versus host disease 11.4 IL10 NOD2 TNF
27 alveolar echinococcosis 11.4 HLA-B TLR4 TNF
28 uveitis 11.4 HLA-B IL10 NOD2 TNF
29 lymphadenitis 11.4 IL10 NOD2 TLR4 TNF
30 streptococcal meningitis 11.4 CRP NOD2 TNF
31 palindromic rheumatism 11.4 CRP MEFV TNF TNFRSF1A
32 pericarditis 11.4 CRP MEFV TNF TNFRSF1A
33 ileitis 11.4 NOD2 TLR4 TNF
34 complex regional pain syndrome 11.4 HLA-B IL10 TNF
35 spondyloarthropathy 1 11.4 CRP HLA-B NOD2 TNF
36 hypersensitivity reaction type iv disease 11.4 FAS NOD2 TNF
37 epstein-barr virus-associated gastric carcinoma 11.4 FAS IL10 TNF
38 reactive arthritis 11.4 CRP HLA-B IL10 TNF
39 adult-onset still's disease 11.4 CRP MEFV TNF
40 tropical endomyocardial fibrosis 11.4 IL10 TNF
41 peritonitis 11.4 CRP IL10 MEFV TNF
42 graft-versus-host disease 11.4 FAS HLA-B IL10 TNF
43 scrub typhus 11.3 CRP IL10 TLR4 TNF
44 immune system disease 11.3 CRP IL10 MEFV TNF
45 echinococcosis 11.3 HLA-B IL10 TNF
46 idiopathic neutropenia 11.3 IL10 TLR4 TNF
47 leprosy 3 11.3 IL10 NOD2 TNF
48 pleurisy 11.3 CRP MEFV TNF
49 hemorrhagic fever with renal syndrome 11.3 CRP IL10 TNF
50 rheumatic disease 11.3 CRP HLA-B IL10 TNF

Graphical network of the top 20 diseases related to Behcet Syndrome:



Diseases related to Behcet Syndrome

Symptoms & Phenotypes for Behcet Syndrome

Symptoms via clinical synopsis from OMIM:

57
Joints:
arthritis

Skin:
raynaud phenomenon
erythema nodosum-like eruptions
superficial thrombophlebitis
pustular skin lesions
hyperirritability

Mouth:
mouth ulcerations

Neuro:
brainstem syndrome
meningoencephalomyelitic syndrome
organic confusional state
schizoaffective disorder

Eyes:
uveitis
iritis
iridocyclitis
hypopyon
choreoretinitis

Hair:
alopecia areata

GU:
genital ulcerations
epididymitis


Clinical features from OMIM:

109650

Human phenotypes related to Behcet Syndrome:

59 32 (show top 50) (show all 78)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 seizures 59 32 occasional (7.5%) Occasional (29-5%) HP:0001250
2 ataxia 59 32 occasional (7.5%) Occasional (29-5%) HP:0001251
3 gait disturbance 59 32 frequent (33%) Frequent (79-30%) HP:0001288
4 hyperreflexia 59 32 occasional (7.5%) Occasional (29-5%) HP:0001347
5 nausea and vomiting 59 32 hallmark (90%) Very frequent (99-80%) HP:0002017
6 developmental regression 59 32 occasional (7.5%) Occasional (29-5%) HP:0002376
7 encephalitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0002383
8 abnormal pyramidal signs 59 32 occasional (7.5%) Occasional (29-5%) HP:0007256
9 cataract 59 32 occasional (7.5%) Occasional (29-5%) HP:0000518
10 arthritis 59 32 hallmark (90%) Very frequent (99-80%) HP:0001369
11 splenomegaly 59 32 occasional (7.5%) Occasional (29-5%) HP:0001744
12 increased intracranial pressure 59 32 occasional (7.5%) Occasional (29-5%) HP:0002516
13 aseptic necrosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0010885
14 malabsorption 59 32 occasional (7.5%) Occasional (29-5%) HP:0002024
15 blindness 59 32 occasional (7.5%) Occasional (29-5%) HP:0000618
16 renal insufficiency 59 32 occasional (7.5%) Occasional (29-5%) HP:0000083
17 retinopathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0000488
18 photophobia 59 32 hallmark (90%) Very frequent (99-80%) HP:0000613
19 fever 59 32 hallmark (90%) Very frequent (99-80%) HP:0001945
20 cranial nerve paralysis 59 32 occasional (7.5%) Occasional (29-5%) HP:0006824
21 fatigue 59 32 hallmark (90%) Very frequent (99-80%) HP:0012378
22 subcutaneous nodule 59 32 hallmark (90%) Very frequent (99-80%) HP:0001482
23 arthralgia 59 32 frequent (33%) Frequent (79-30%) HP:0002829
24 myocardial infarction 59 32 occasional (7.5%) Occasional (29-5%) HP:0001658
25 abdominal pain 59 32 frequent (33%) Frequent (79-30%) HP:0002027
26 pulmonary embolism 59 32 occasional (7.5%) Occasional (29-5%) HP:0002204
27 abnormal blistering of the skin 59 32 frequent (33%) Frequent (79-30%) HP:0008066
28 irritability 59 32 occasional (7.5%) Occasional (29-5%) HP:0000737
29 weight loss 59 32 occasional (7.5%) Occasional (29-5%) HP:0001824
30 acne 59 32 frequent (33%) Frequent (79-30%) HP:0001061
31 venous thrombosis 59 32 frequent (33%) Frequent (79-30%) HP:0004936
32 pancreatitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001733
33 anorexia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002039
34 migraine 59 32 hallmark (90%) Very frequent (99-80%) HP:0002076
35 memory impairment 59 32 occasional (7.5%) Occasional (29-5%) HP:0002354
36 cerebral ischemia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002637
37 myalgia 59 32 hallmark (90%) Very frequent (99-80%) HP:0003326
38 paresthesia 59 32 occasional (7.5%) Occasional (29-5%) HP:0003401
39 glomerulopathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0100820
40 keratoconjunctivitis sicca 59 32 occasional (7.5%) Occasional (29-5%) HP:0001097
41 abnormal myocardium morphology 59 32 occasional (7.5%) Occasional (29-5%) HP:0001637
42 mitral regurgitation 59 32 occasional (7.5%) Occasional (29-5%) HP:0001653
43 vertigo 59 32 occasional (7.5%) Occasional (29-5%) HP:0002321
44 hemoptysis 59 32 occasional (7.5%) Occasional (29-5%) HP:0002105
45 gastrointestinal hemorrhage 59 32 frequent (33%) Frequent (79-30%) HP:0002239
46 pericarditis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001701
47 endocarditis 59 32 occasional (7.5%) Occasional (29-5%) HP:0100584
48 meningitis 59 32 hallmark (90%) Very frequent (99-80%) HP:0001287
49 vasculitis 59 32 hallmark (90%) Very frequent (99-80%) HP:0002633
50 arterial thrombosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0004420

UMLS symptoms related to Behcet Syndrome:


angina pectoris, chest pain, edema, exanthema, halitosis, oral manifestations, pruritus, snoring

GenomeRNAi Phenotypes related to Behcet Syndrome according to GeneCards Suite gene sharing:

26 (show top 50) (show all 65)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.23 IL10
2 Increased shRNA abundance (Z-score > 2) GR00366-A-101 10.23 CCR1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-103 10.23 HLA-B
4 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.23 ADA2 CCR1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-106 10.23 ADA2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-107 10.23 ADA2 C4A
7 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.23 HLA-B
8 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.23 C4A CCR1 TLR4 IL10
9 Increased shRNA abundance (Z-score > 2) GR00366-A-114 10.23 TLR4
10 Increased shRNA abundance (Z-score > 2) GR00366-A-116 10.23 C4A
11 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.23 HLA-B
12 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.23 CCR1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-125 10.23 IL10
14 Increased shRNA abundance (Z-score > 2) GR00366-A-128 10.23 TLR4 IL10
15 Increased shRNA abundance (Z-score > 2) GR00366-A-130 10.23 ADA2
16 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10.23 IL10
17 Increased shRNA abundance (Z-score > 2) GR00366-A-137 10.23 C4A
18 Increased shRNA abundance (Z-score > 2) GR00366-A-147 10.23 CCR1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.23 IL10
20 Increased shRNA abundance (Z-score > 2) GR00366-A-156 10.23 HLA-B
21 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.23 ADA2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.23 C4A IL10
23 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.23 ADA2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.23 TLR4
25 Increased shRNA abundance (Z-score > 2) GR00366-A-174 10.23 NOD2
26 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.23 NOD2
27 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.23 HLA-B
28 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.23 C4A HLA-B ADA2 NOD2
29 Increased shRNA abundance (Z-score > 2) GR00366-A-192 10.23 NOD2
30 Increased shRNA abundance (Z-score > 2) GR00366-A-195 10.23 CCR1 NOD2
31 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.23 CCR1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.23 IL10
33 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.23 ADA2
34 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.23 NOD2 IL10
35 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.23 IL10
36 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.23 IL10
37 Increased shRNA abundance (Z-score > 2) GR00366-A-31 10.23 HLA-B
38 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.23 CCR1 NOD2
39 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.23 C4A NOD2
40 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.23 ADA2
41 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.23 ADA2
42 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.23 ADA2 IL10
43 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.23 C4A CCR1
44 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.23 IL10
45 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.23 HLA-B
46 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.23 HLA-B
47 Increased shRNA abundance (Z-score > 2) GR00366-A-8 10.23 C4A
48 Increased shRNA abundance (Z-score > 2) GR00366-A-80 10.23 ADA2 IL10
49 Increased shRNA abundance (Z-score > 2) GR00366-A-82 10.23 CCR1 IL10
50 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.23 IL10

MGI Mouse Phenotypes related to Behcet Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.18 NOD2 FAS PSTPIP1 STAT4 IL10 TLR4
2 homeostasis/metabolism MP:0005376 10.1 NOD2 FAS STAT4 IL10 TLR4 IL12A
3 immune system MP:0005387 10.1 FAS PSTPIP1 STAT4 IL10 TLR4 IL12A
4 digestive/alimentary MP:0005381 10.01 NOD2 FAS IL10 TLR4 CCR1 IL23R
5 liver/biliary system MP:0005370 9.7 FAS IL10 TLR4 CCR1 MEFV TNF
6 neoplasm MP:0002006 9.5 FAS IL10 TLR4 IL12A IL23R TNF
7 respiratory system MP:0005388 9.17 FAS IL10 TLR4 IL12A CCR1 TNF

Drugs & Therapeutics for Behcet Syndrome

Drugs for Behcet Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 87)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 83-43-2 6741
2
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-24-8 5755
3
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4 67-73-2 6215
4 Antiemetics Phase 4,Not Applicable
5 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Not Applicable
6 Antineoplastic Agents, Hormonal Phase 4,Not Applicable
7 Autonomic Agents Phase 4,Not Applicable
8 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
9 glucocorticoids Phase 4,Not Applicable
10 Hormone Antagonists Phase 4,Not Applicable
11 Hormones Phase 4,Not Applicable
12 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Not Applicable
13 Methylprednisolone acetate Phase 4,Phase 3,Phase 2,Not Applicable
14 Methylprednisolone Hemisuccinate Phase 4,Phase 3,Phase 2,Not Applicable
15 Neuroprotective Agents Phase 4,Not Applicable
16 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
17 Prednisolone acetate Phase 4,Phase 3,Phase 2,Not Applicable
18 Prednisolone hemisuccinate Phase 4,Phase 3,Phase 2,Not Applicable
19 Prednisolone phosphate Phase 4,Phase 3,Phase 2,Not Applicable
20 Protective Agents Phase 4,Not Applicable
21 Pharmaceutical Solutions Phase 4,Phase 3,Phase 1
22 Omega 3 Fatty Acid Nutraceutical Phase 4
23
Adalimumab Approved Phase 3,Phase 2 331731-18-1 16219006
24
Infliximab Approved Phase 3,Phase 1,Phase 2 170277-31-3
25
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
26
Apremilast Approved, Investigational Phase 3,Phase 2 608141-41-9 11561674
27
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
28 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
29 Immunosuppressive Agents Phase 3,Phase 2,Not Applicable,Early Phase 1
30 Anti-Infective Agents Phase 3,Phase 2,Not Applicable
31 Cyclosporins Phase 3
32 Dermatologic Agents Phase 3,Phase 1,Phase 2,Not Applicable
33 Anti-Bacterial Agents Phase 3,Phase 2
34 Analgesics Phase 3,Phase 2,Not Applicable
35 Analgesics, Non-Narcotic Phase 3,Phase 2,Not Applicable
36 Anti-Inflammatory Agents, Non-Steroidal Phase 3,Phase 2,Not Applicable
37 Antifungal Agents Phase 3
38 Antiviral Agents Phase 3,Phase 2
39 Calcineurin Inhibitors Phase 3
40 Interferon-alpha Phase 3,Phase 2
41 interferons Phase 3,Phase 2
42 Antibodies Phase 3,Phase 2
43 Antibodies, Monoclonal Phase 3,Phase 2
44 Immunoglobulins Phase 3,Phase 2
45 Angiogenesis Inhibitors Phase 3,Phase 2
46 Angiogenesis Modulating Agents Phase 3,Phase 2
47 Alkylating Agents Phase 3
48 Antineoplastic Agents, Alkylating Phase 3
49
Azathioprine Approved Phase 2 446-86-6 2265
50
Methotrexate Approved Phase 2,Not Applicable 1959-05-2, 59-05-2 126941

Interventional clinical trials:

(show top 50) (show all 71)
# Name Status NCT ID Phase Drugs
1 The Efficacy of Methylprednisolone in the Treatment of Patients With Ocular Involvement in Behcet's Disease Unknown status NCT01306955 Phase 4 methylorednisolone
2 Flucinolone Acetonide Implant for Treating Refractory Ocular Behcet's Disease Unknown status NCT00720928 Phase 4 flucinolone acetonide
3 Saline vs. Lactated Ringers for Emergency Department IV Fluid Resuscitation Completed NCT03133767 Phase 4 Lactated Ringer Solution;Normal Saline 0.9% Infusion Solution Bag
4 Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels Terminated NCT00578578 Phase 4
5 A Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease Completed NCT01243671 Phase 3
6 Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions Completed NCT01532570 Phase 3 TA-650
7 Phase III Study in Refractory Behcet's Disease Completed NCT00995709 Phase 3 AIN457;AIN457;Placebo
8 Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet`s Disease (INCYTOB) Completed NCT00167583 Phase 3 Cyclosporin A;Interferon-alpha2a
9 Efficacy of Humira in Behcet Patients With Arthritis Completed NCT01497717 Phase 3 Adalimumab (Humira)
10 Interferon α2a Versus Cyclosporine for Refractory Behçet`s Disease Uveitis Recruiting NCT03209219 Phase 3 Interferon Alfa-2A;Cyclosporine Pill
11 Thalidomide Versus Infliximab in New Onset Crohn's Disease With Poor Prognostic Factors Recruiting NCT03221166 Phase 3 Thalidomide;Infliximab
12 A Study to Evaluate Efficacy and Safety of Infliximab in Participant With Moderate-to-Severe Refractory Intestinal Behcet's Disease Active, not recruiting NCT02505568 Phase 3 Infliximab
13 A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behcet's Disease Active, not recruiting NCT02307513 Phase 3 Apremilast (CC-10004);Placebo
14 Induction Therapy With Anti-TNFα vs Cyclophosphamide in Severe Behçet Disease Not yet recruiting NCT03371095 Phase 3 Infliximab;Cyclophosphamide
15 Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis Terminated NCT02258867 Phase 3 Placebo;Gevokizumab
16 Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (EYEGUARD™-B) Terminated NCT01965145 Phase 3 Gevokizumab;Placebo
17 Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis Terminated NCT01095250 Phase 3 AIN457;AIN457;AIN457;Placebo
18 Long-term Safety of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis (EYEGUARD-X) Terminated NCT02375685 Phase 3
19 An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data Terminated NCT02258854 Phase 3 Dose 2 gevokizumab
20 Colchicine Randomized Double-Blind Controlled Crossover Study in Behcet's Disease Completed NCT00700297 Phase 2 Colchicine;Placebo
21 A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease Completed NCT00866359 Phase 2 Apremilast (CC-10004);Placebo
22 Rituximab for the Treatment of Severe Ocular Manifestations of Behcet's Disease Completed NCT00664599 Phase 2 Rituximab;Cytotoxic Combination
23 Intravitreal Infliximab in Refractory Uveitis in Behcet's Disease: A Safety and Efficacy Clinical Study Completed NCT02620618 Phase 1, Phase 2 Intravitreal Infliximab
24 Low Dose Interferon Alpha Treatment for Oral Ulcers of Behcet's Disease Completed NCT00483184 Phase 2
25 HAT in Eye Complications of Behcet's Disease Completed NCT00001865 Phase 2 Daclizumab
26 Anakinra for Behcet s Disease Completed NCT01441076 Phase 1, Phase 2 Anakinra
27 Ilaris (Canakinumab) in the Schnitzler Syndrome Completed NCT01245127 Phase 2 Ilaris
28 Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Subjects With Moderate-To-Severe Plaque-Type Psoriasis Completed NCT01988103 Phase 2 Apremilast;Apremilast;Placebo
29 Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease Recruiting NCT02648581 Phase 2 Subcutaneous Ustekinumab
30 1 Year Canakinumab Treatment in Behcet's Disease Patients With Neurologic or Vascular Involvement Recruiting NCT02756650 Phase 2 drug administration
31 Tocilizumab for the Treatment of Refractory Behcet's Uveitis Recruiting NCT03554161 Phase 2
32 Randomized Trial Comparing Efficacy of Adalimumab, Anakinra and Tocilizumab in Non-infectious Refractory Uveitis Recruiting NCT02929251 Phase 2 Anakinra;Tocilizumab;Adalimumab
33 Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases Recruiting NCT01988506 Phase 2 Interleukin 2
34 Anti IL-18 (GSK1070806) in Behcet's Disease Not yet recruiting NCT03522662 Phase 2 GSK1070806
35 Tocilizumab for the Treatment of Behcet's Syndrome Terminated NCT01693653 Phase 2 Tocilizumab
36 A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome / Muckle-Wells Syndrome and Behcet's Disease Withdrawn NCT01211977 Phase 1, Phase 2 XOMA 052
37 Stem Cell Transplantation for the Treatment of Knee Osteoarthritis Unknown status NCT00550524 Phase 1
38 Stem Cell Transplantation in Ocular Lesions of Behcet's Disease Terminated NCT00550498 Phase 1
39 Hematopoietic Stem Cell Support in Vasculitis Terminated NCT00278512 Phase 1
40 Etanercept: Single Blind Control Study in Ocular Manifestations of Behcet's Disease Unknown status NCT00931957 Not Applicable Etanercept, Methotrexate, Prednisolone
41 The Serum Angiotensin Converting Enzyme and Lysozyme Levels in Patients Non-infectious and Infectious Uveitis Unknown status NCT02627209 Not Applicable
42 Causes of Visual Loss in Retinal Disease Unknown status NCT01613963 Immunosuppressive Agents
43 Psychological Symptoms in Patients With Behcet's Disease by SCL90-R Completed NCT00699985
44 Special Investigation in Patients With Intestinal Behcet's Disease (All Case Investigation) Completed NCT01960790
45 Behçet's Disease and Eosinophil Cationic Protein Completed NCT01584778
46 MEVALONATE KINASE GENE MUTATIONS AND THEIR CLINICAL CORRELATIONS IN BEHÇET'S DISEASE Completed NCT01780363
47 The Relationship Between Serum Levels of Angiogenin, bFGF, VEGF and Ocular Involvement in Patients With Behçet's Disease Completed NCT01720628
48 Educational Needs of Patients With Systemic Vasculitis Completed NCT02190929
49 Biological Markers in Retinal Vasculitis Completed NCT00050492
50 Uveitis Gene-Expression Profiling Completed NCT00874471

Search NIH Clinical Center for Behcet Syndrome

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Behcet Syndrome cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Behcet Syndrome:
Bone marrow-derived stem cells for treatment of ocular lesions Behcet's disease
Embryonic/Adult Cultured Cells Related to Behcet Syndrome:
Bone marrow-derived stem cells PMIDs: 21199472 23773637

Cochrane evidence based reviews: behcet syndrome

Genetic Tests for Behcet Syndrome

Anatomical Context for Behcet Syndrome

MalaCards organs/tissues related to Behcet Syndrome:

41
Eye, Skin, Brain, Spinal Cord, Bone, Neutrophil, T Cells

Publications for Behcet Syndrome

Articles related to Behcet Syndrome:

# Title Authors Year
1
Delayed Vasospasm after Aneurysmal Subarachnoid Hemorrhage in Behcet Syndrome. ( 27114963 )
2016
2
Clinical and Ultrasonographic Evaluation of Lower-extremity Vein Thrombosis in Behcet Syndrome: An Observational Study. ( 26554787 )
2015
3
JAK2 (V617F) mutation is not associated with thrombosis in Behcet syndrome. ( 22203033 )
2012
4
Summary of workshop on recurrent aphthous stomatitis and Behcet syndrome. ( 281401 )
1978

Variations for Behcet Syndrome

ClinVar genetic disease variations for Behcet Syndrome:

6
(show all 34)
# Gene Variation Type Significance SNP ID Assembly Location
1 TNFRSF1A NM_001065.3(TNFRSF1A): c.596T> C (p.Ile199Thr) single nucleotide variant Uncertain significance rs104895247 GRCh37 Chromosome 12, 6440048: 6440048
2 TNFRSF1A NM_001065.3(TNFRSF1A): c.596T> C (p.Ile199Thr) single nucleotide variant Uncertain significance rs104895247 GRCh38 Chromosome 12, 6330882: 6330882
3 NOD2 NM_022162.2(NOD2): c.2446G> A single nucleotide variant Pathogenic rs886040969 GRCh37 Chromosome 16, 50746268: 50746268
4 NOD2 NM_022162.2(NOD2): c.2446G> A single nucleotide variant Pathogenic rs886040969 GRCh38 Chromosome 16, 50712357: 50712357
5 TNFRSF1A NM_001065.3(TNFRSF1A): c.463C> T single nucleotide variant Pathogenic rs886039866 GRCh37 Chromosome 12, 6442542: 6442542
6 TNFRSF1A NM_001065.3(TNFRSF1A): c.463C> T single nucleotide variant Pathogenic rs886039866 GRCh38 Chromosome 12, 6333376: 6333376
7 NOD2 NM_022162.2(NOD2): c.2197G> T single nucleotide variant Pathogenic rs746055479 GRCh38 Chromosome 16, 50712108: 50712108
8 NOD2 NM_022162.2(NOD2): c.2197G> T single nucleotide variant Pathogenic rs746055479 GRCh37 Chromosome 16, 50746019: 50746019
9 NOD2 NM_022162.2(NOD2): c.241C> G single nucleotide variant Pathogenic rs34936594 GRCh37 Chromosome 16, 50733566: 50733566
10 NOD2 NM_022162.2(NOD2): c.241C> G single nucleotide variant Pathogenic rs34936594 GRCh38 Chromosome 16, 50699655: 50699655
11 NOD2 NM_022162.2(NOD2): c.1045C> T (p.Leu349Phe) single nucleotide variant Pathogenic rs752615209 GRCh38 Chromosome 16, 50710956: 50710956
12 NOD2 NM_022162.2(NOD2): c.1045C> T (p.Leu349Phe) single nucleotide variant Pathogenic rs752615209 GRCh37 Chromosome 16, 50744867: 50744867
13 PSTPIP1 NM_003978.4(PSTPIP1): c.364G> A (p.Val122Ile) single nucleotide variant Uncertain significance rs886041107 GRCh37 Chromosome 15, 77320202: 77320202
14 PSTPIP1 NM_003978.4(PSTPIP1): c.364G> A (p.Val122Ile) single nucleotide variant Uncertain significance rs886041107 GRCh38 Chromosome 15, 77027861: 77027861
15 PSTPIP1 NM_003978.4(PSTPIP1): c.865G> C (p.Asp289His) single nucleotide variant Pathogenic rs774164456 GRCh38 Chromosome 15, 77032888: 77032888
16 PSTPIP1 NM_003978.4(PSTPIP1): c.865G> C (p.Asp289His) single nucleotide variant Pathogenic rs774164456 GRCh37 Chromosome 15, 77325229: 77325229
17 PSTPIP1 NM_003978.4(PSTPIP1): c.203C> T (p.Thr68Met) single nucleotide variant Likely benign rs201872851 GRCh38 Chromosome 15, 77018522: 77018522
18 PSTPIP1 NM_003978.4(PSTPIP1): c.203C> T (p.Thr68Met) single nucleotide variant Likely benign rs201872851 GRCh37 Chromosome 15, 77310863: 77310863
19 ADA2 NM_001282225.1(ADA2): c.145C> T (p.Arg49Trp) single nucleotide variant Uncertain significance rs199614299 GRCh38 Chromosome 22, 17209533: 17209533
20 ADA2 NM_001282225.1(ADA2): c.145C> T (p.Arg49Trp) single nucleotide variant Uncertain significance rs199614299 GRCh37 Chromosome 22, 17690423: 17690423
21 ADA2 NM_001282225.1(ADA2): c.927G> A (p.Met309Ile) single nucleotide variant Likely benign rs146597836 GRCh38 Chromosome 22, 17189987: 17189987
22 ADA2 NM_001282225.1(ADA2): c.927G> A (p.Met309Ile) single nucleotide variant Likely benign rs146597836 GRCh37 Chromosome 22, 17670877: 17670877
23 ADA2 NM_001282225.1(ADA2): c.740C> T (p.Ala247Val) single nucleotide variant Pathogenic rs750868279 GRCh38 Chromosome 22, 17203576: 17203576
24 ADA2 NM_001282225.1(ADA2): c.740C> T (p.Ala247Val) single nucleotide variant Pathogenic rs750868279 GRCh37 Chromosome 22, 17684466: 17684466
25 MEFV NM_000243.2(MEFV): c.1211A> G (p.His404Arg) single nucleotide variant Pathogenic rs755659290 GRCh38 Chromosome 16, 3249480: 3249480
26 MEFV NM_000243.2(MEFV): c.1211A> G (p.His404Arg) single nucleotide variant Pathogenic rs755659290 GRCh37 Chromosome 16, 3299480: 3299480
27 MEFV NM_000243.2(MEFV): c.1099C> G (p.Leu367Val) single nucleotide variant Pathogenic rs1057519328 GRCh38 Chromosome 16, 3249592: 3249592
28 MEFV NM_000243.2(MEFV): c.1099C> G (p.Leu367Val) single nucleotide variant Pathogenic rs1057519328 GRCh37 Chromosome 16, 3299592: 3299592
29 TNFRSF1A NM_001065.3(TNFRSF1A): c.935G> A (p.Arg312Lys) single nucleotide variant Conflicting interpretations of pathogenicity rs200900510 GRCh37 Chromosome 12, 6439066: 6439066
30 TNFRSF1A NM_001065.3(TNFRSF1A): c.935G> A (p.Arg312Lys) single nucleotide variant Conflicting interpretations of pathogenicity rs200900510 GRCh38 Chromosome 12, 6329900: 6329900
31 ADA2 NM_001282225.1(ADA2): c.1045G> A (p.Val349Ile) single nucleotide variant Benign rs74317375 GRCh37 Chromosome 22, 17669265: 17669265
32 ADA2 NM_001282225.1(ADA2): c.1045G> A (p.Val349Ile) single nucleotide variant Benign rs74317375 GRCh38 Chromosome 22, 17188375: 17188375
33 MEFV NM_000243.2(MEFV): c.332G> A (p.Gly111Glu) single nucleotide variant Pathogenic rs751454741 GRCh37 Chromosome 16, 3304736: 3304736
34 MEFV NM_000243.2(MEFV): c.332G> A (p.Gly111Glu) single nucleotide variant Pathogenic rs751454741 GRCh38 Chromosome 16, 3254736: 3254736

Copy number variations for Behcet Syndrome from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 241985 8 6835170 6856724 Copy number DEFA1 Behcet''s disease

Expression for Behcet Syndrome

Search GEO for disease gene expression data for Behcet Syndrome.

Pathways for Behcet Syndrome

Pathways related to Behcet Syndrome according to GeneCards Suite gene sharing:

(show all 36)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.87 ADA2 C4A CCR1 CRP ERAP1 HLA-B
2
Show member pathways
13.37 CCR1 FAS IL10 IL12A IL23R STAT4
3
Show member pathways
13.33 CCR1 HLA-B IL10 IL12A IL23R NOD2
4
Show member pathways
13.26 CCR1 FAS IL10 IL12A IL23R TNF
5
Show member pathways
12.8 C4A FAS HLA-B IL10 IL12A KLRC4
6
Show member pathways
12.76 FAS HLA-B IL12A TLR4 TNF TNFRSF1A
7
Show member pathways
12.66 FAS IL10 IL12A MEFV NOD2 PSTPIP1
8
Show member pathways
12.58 HLA-B IL10 IL12A IL23R STAT4 TNF
9 12.54 FAS IL10 STAT4 TNF TNFRSF1A
10
Show member pathways
12.47 IL12A TLR4 TNF TNFRSF1A
11
Show member pathways
12.38 FAS IL10 PSTPIP1 TNF
12
Show member pathways
12.38 CCR1 FAS HLA-B STAT4 TLR4 TNF
13
Show member pathways
12.22 IL10 IL12A TLR4 TNF TNFRSF1A
14
Show member pathways
12.18 IL10 IL12A IL23R STAT4 TLR4 TNF
15
Show member pathways
12.17 FAS STAT4 TLR4 TNF TNFRSF1A
16 12.1 IL10 IL12A NOD2 TLR4 TNF TNFRSF1A
17 11.96 IL10 IL12A IL23R TNF
18 11.93 FAS NOD2 TNF TNFRSF1A
19
Show member pathways
11.92 IL10 IL12A IL23R NOD2 STAT4 TLR4
20 11.87 IL10 IL12A TLR4 TNF
21 11.87 CCR1 IL10 IL12A IL23R STAT4
22 11.82 TLR4 TNF TNFRSF1A
23 11.76 IL10 IL12A IL23R TNF
24 11.71 IL10 IL12A TNF
25 11.69 TLR4 TNF TNFRSF1A
26 11.57 IL12A TLR4 TNF
27 11.56 TLR4 TNF TNFRSF1A
28 11.54 C4A IL10 IL12A TLR4 TNF
29 11.52 FAS TNF TNFRSF1A
30 11.49 IL12A TLR4 TNF
31 11.49 IL10 IL12A TLR4 TNF
32 11.45 FAS TNF TNFRSF1A
33 11.33 IL10 TLR4 TNF
34 11.32 FAS IL10 IL12A TNF
35 11.11 NOD2 TNF TNFRSF1A
36 10.71 CCR1 IL10 IL12A TNF TNFRSF1A

GO Terms for Behcet Syndrome

Cellular components related to Behcet Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.81 ADA2 C4A CRP ERAP1 FAS IL10
2 extracellular space GO:0005615 9.56 ADA2 C4A CRP ERAP1 IL10 IL12A
3 cell surface GO:0009986 9.17 FAS HLA-B IL12A NOD2 TLR4 TNF

Biological processes related to Behcet Syndrome according to GeneCards Suite gene sharing:

(show all 48)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.98 CCR1 NOD2 TLR4 TNF
2 innate immune response GO:0045087 9.95 C4A CRP IL23R MEFV NOD2 PSTPIP1
3 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.89 NOD2 TLR4 TNF TNFRSF1A
4 defense response to Gram-positive bacterium GO:0050830 9.88 CRP IL12A TNF
5 defense response to bacterium GO:0042742 9.88 IL10 NOD2 TLR4 TNF TNFRSF1A
6 regulation of inflammatory response GO:0050727 9.87 NOD2 TLR4 TNF
7 immune system process GO:0002376 9.86 C4A ERAP1 HLA-B IL23R MEFV NOD2
8 cellular response to mechanical stimulus GO:0071260 9.85 FAS TLR4 TNFRSF1A
9 cellular response to lipopolysaccharide GO:0071222 9.85 IL10 IL12A TLR4 TNF
10 positive regulation of JNK cascade GO:0046330 9.84 NOD2 TLR4 TNF
11 negative regulation of inflammatory response GO:0050728 9.83 IL10 MEFV NOD2 TNFRSF1A
12 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.82 IL12A IL23R TNFRSF1A
13 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.8 TLR4 TNF TNFRSF1A
14 response to lipopolysaccharide GO:0032496 9.8 FAS IL10 IL12A IL23R TLR4 TNFRSF1A
15 positive regulation of interleukin-6 production GO:0032755 9.77 NOD2 TLR4 TNF
16 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.76 NOD2 TLR4 TNF
17 interleukin-12-mediated signaling pathway GO:0035722 9.75 IL10 IL12A STAT4
18 extrinsic apoptotic signaling pathway GO:0097191 9.73 FAS IL12A TNF
19 apoptotic signaling pathway GO:0097190 9.73 FAS TLR4 TNF TNFRSF1A
20 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.7 NOD2 TLR4
21 negative regulation of growth of symbiont in host GO:0044130 9.7 IL10 TNF
22 positive regulation of interleukin-17 production GO:0032740 9.7 IL23R NOD2
23 cytokine-mediated signaling pathway GO:0019221 9.7 CCR1 IL10 IL12A IL23R STAT4 TNF
24 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.69 IL10 TNF
25 interferon-gamma production GO:0032609 9.69 IL12A TLR4
26 positive regulation of interleukin-8 production GO:0032757 9.69 NOD2 TLR4 TNF
27 negative regulation of interleukin-12 production GO:0032695 9.68 IL10 MEFV
28 positive regulation of T cell mediated cytotoxicity GO:0001916 9.68 IL12A IL23R
29 negative regulation of interleukin-17 production GO:0032700 9.68 IL12A TLR4
30 interleukin-35-mediated signaling pathway GO:0070757 9.67 IL12A STAT4
31 negative regulation of interleukin-6 production GO:0032715 9.67 IL10 TLR4 TNF
32 positive regulation of interferon-gamma production GO:0032729 9.67 IL12A IL23R TLR4 TNF
33 negative regulation of lipid storage GO:0010888 9.66 CRP TNF
34 positive regulation of ceramide biosynthetic process GO:2000304 9.66 TNF TNFRSF1A
35 interleukin-23-mediated signaling pathway GO:0038155 9.65 IL23R STAT4
36 positive regulation of lymphocyte proliferation GO:0050671 9.65 IL12A TLR4
37 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.64 TLR4 TNF
38 death-inducing signaling complex assembly GO:0071550 9.64 TNF TNFRSF1A
39 endothelial cell apoptotic process GO:0072577 9.63 IL10 TNF
40 positive regulation of osteoclast differentiation GO:0045672 9.63 CCR1 IL23R TNF
41 positive regulation of MHC class II biosynthetic process GO:0045348 9.62 IL10 TLR4
42 regulation of establishment of endothelial barrier GO:1903140 9.62 TNF TNFRSF1A
43 negative regulation of cytokine secretion involved in immune response GO:0002740 9.61 IL10 TNF
44 necroptotic signaling pathway GO:0097527 9.61 FAS TNF
45 positive regulation of NK T cell activation GO:0051135 9.57 IL12A IL23R
46 immune response GO:0006955 9.56 CCR1 FAS HLA-B IL10 IL12A TLR4
47 receptor biosynthetic process GO:0032800 9.54 IL10 TNF
48 inflammatory response GO:0006954 9.4 C4A CCR1 CRP FAS IL10 IL23R

Molecular functions related to Behcet Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.7 CRP FAS MEFV PSTPIP1 STAT4 TNF
2 complement component C1q binding GO:0001849 9.26 C4A CRP
3 tumor necrosis factor binding GO:0043120 8.96 FAS TNFRSF1A
4 interleukin-12 receptor binding GO:0005143 8.62 IL12A IL23R
5 protein binding GO:0005515 10.25 C4A CCR1 CRP ERAP1 FAS HLA-B

Sources for Behcet Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....